Science Pool

Take a Ride on the Evotec "Data-Driven R&D Autobahn to Cures"

5 Virtual Sessions over 5 Days

Date: 6 - 10 November 2021 Online | 9 - 11 November 2021 Fiera Milano

Location: Virtual

• Learn how Evotec is using data and science across treatment modalities to accelerate innovation in the area of precision medicine to deliver enhanced speed, lower cost, and predictive efficacy

• Find out about our efforts in AI/ML in the design and development of both small molecules and antibodies, the importance of  biomarker development, targeting RNA, and our approaches to target validation

Day 1:
Drug Discovery in Evotec Multiverse: Knowledge-driven Integrated R&D

Presented by: Adam Davenport, Tim James and Christophe Boldron
When | Monday 6 December @ 11am EST | 8am PST | 4pm GMT | 5pm CET

Day 2:
The Importance of Precision Medicine: How Biomarkers Optimise Translation from Bench to Bedside and Back

Presented by: Elizabeth van der Kam, Christoph Schaab
When |Tuesday 7 December @ 11am EST | 8am PST | 4pm GMT | 5pm CET

Day 3:
The Early Bird Catches the Helix: Expanding the Druggable Target Space to RNA

Presented by: Steffen Grimm, Hilary Brooks
When | Wednesday 8 December @ 11am EST | 8am PST | 4pm GMT | 5pm CET

Day 4:
Do Firefighters cause Fires? Establishing Real Disease Associations through Target Validation

Presented by: Hauke Cornils, Susan Boyce
When |Thursday 9 December @ 11am EST | 8am PST | 4pm GMT | 5pm CET

Day 5:
Translate your Idea into Product: AI-Driven Antibody Discovery at Evotec

Presented by: Barbara Bachler-Konetzki, Randal Ketchem, Maria Pilla
When | Friday 10 December @ 11am EST | 8am PST | 4pm GMT | 5pm CET

Each session will take approx. 45 min including Q&A. You will need to register for each day separately to reserve your seat.

RESERVE YOUR SEAT

This article forms a book chapter in Artificial Intelligence in Drug Design.

In this review article, we provide the latest insights into de novo design approaches based on  artificial intelligence (AI) algorithms with a specific focus on ligand-based methods.

It includes:

• a background to de novo design approaches developed prior to the use of AI
• an overview of AI and commonly employed neural network architectures used in ligand based de novo design
• a list of more than 100 deep generative models reported in the literature from 2017-2020
• current applications of deep generative approaches in the drug discovery context
• an insight into future applications of deep generative models in de novo drug design 

LEARN MORE

Date: 18th November 2021

Venue: Virtual

Attendee: Dr Alastair Parkes, Group Leader at Evotec will be presenting on "Novel LpxA inhibitors targeting Pseudomonas aeruginosa"

Learn More About the EADA Conference

Date: 15th-16th November 2021

Location: ENS Campus Gerland, Lyon, France

Attendee: Antoine Alam, VP Virology will be presenting on "CD40 agonists boost IFN-induced signaling pathway and subsequent anti-HBV response in vitro and in vivo"

Huge Watson, Virology Clinical Development will be presenting a poster entitled "Household clustering suggests a novel chemoprophylaxis trial design for an arboviral disease"

Francesca Bernardini, VP In Vitro Biology, Sébastien Coyne, Group Leader In Vitro Biology, Kara Carter, Virology Entrepreneur in Residence, Lilia Boucinha, Team Leader, Bioinformatics

Learn More About I4ID

Transient Receptor Potential Melastatin 5 (TRPM5) is an intracellular calcium-activated cation-selective ion channel which is expressed in a variety of cells and tissues. Dysfunction of the TRPM5 channel has been linked to a number of pathological conditions including diabetes, inflammatory responses, enteric infections and parasitic infections. Identifying sufficiently selective agonists or positive modulators of the TRPM5 channel has, to date, proved challenging which has limited its potential as a drug target.   

In this publication, we focus on:

• the development of a high throughput screen using a fluorescent membrane potential assay for primary hit identification screening and selectivity assessment of TRPM5 channel positive modulators 
• use of medium and high throughput electrophysiology assays (QPatch HTX and SyncroPatch 384PE) as follow-up screens to confirm activity and selectivity of identified hits
• the SyncroPatch 384PE assay for structure-activity relationship (SAR) expansion of the identified chemical series

LEARN MORE

Fireside Chat at BIO-Europe 2021

Evotec Chief Scientific Officer, Dr Cord Dohrmann, talks to Dr Hubert Birner, Managing Partner at TVM Capital Life Sciences, about how Evotec has built an impressive and innovative platform.

WATCH NOW

Loss of heart myocardium is considered to be an irreversible process which can eventually lead to heart failure. Adult cardiomyocytes divide at a rate of less than 1% per year and no cardiac stem or progenitor cell type contribute significantly to the replacement of lost myocytes. One approach being pursued to replace lost heart muscle and regenerate the heart is the use of stem cell-derived cardiomyocytes.

In this publication, we focus on an in-depth review of the use of human pluripotent stem-cell derived cardiomyocytes in heart regeneration including:

• a background to cardiac regeneration and the approaches used to address this
• preclinical research and achievements in the use of cell therapy and stem cell-derived cardiomyocytes for the replacement of lost heart muscle 
• an overview of existing open questions such as how the technology works, the duration of effect, patient selection, immunological issues and how to reduce risk
• a summary of the clinical trials currently ongoing in this field

LEARN MORE

Date: 26th -27th October 2021

Location: London, UK 

Evotec is a sponsor of Discovery UK 2021 (organised by Oxford Global)

Our Senior Vice President, Global Head of Protein Sciences, John Barker will present on "Discovery of Novel UDP-N-Acetylglucosamine Acyltransferase (LpxA) Inhibitors With Activity Against Pseudomonas aeruginosa" on October 27th at 9:50am in the Molecular Drug Design & Medicinal Chemistry, & The Optimisation of HITS stream

Our delegates: Jason Brown, Oksana Nikolayenko, John Barker

Learn more about Discovery UK 2021

Date: 28th -29th October 2021

Location: Wequassett Resort & Golf Club in Chatham, MA on Cape Cod, US

Evotec is a sponsor of Convergence Forum 2021

Our Global Head, Integrated Drug Discovery, Karen Lackey will be speaking at the mainstage session on Thursday, October 28th 11:45 AM - 12:30 PM on “Today's Applications of AI in Drug Discovery — and What Comes Next” with Kristen Fortney, PhD, CEO and co-founder at BioAge - Moderator: Rich Kivel, Managing Director, GrayBella Capital

Attendees: Ryan Brady, Itta MacNevin, Karen Lackey

Learn more about Convergence Forum 2021